Merck

(IN BRIEF) EQT has unveiled its EQT Healthcare Growth Strategy and revealed its initial investment in Mabtech, acquired from the IK Small Cap II Fund. The strategy aims to capitalize on long-term healthcare trends, leveraging scientific breakthroughs, technology advancements, and … Read the full press release →

(IN BRIEF) The global life sciences industry has witnessed a resurgence in mergers and acquisitions (M&A) activity, with investments totaling $191 billion by December 10, 2023, compared to $142 billion in 2022. Although the number of completed deals decreased, the … Read the full press release →

(IN BRIEF) Merck KGaA, Darmstadt, Germany, has entered into a licensing agreement with Inspirna, Inc. for ompenaclid (RGX-202), a first-in-class oral inhibitor of the creatine transport channel SLC6A8, and SLC6A8-targeting follow-on compounds, currently under Phase II evaluation for the second-line … Read the full press release →